Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,432 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,449 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05673577 | Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients | completed | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05924256 | A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing | active not recruiting | Phase 2 | 88 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing |
| recruiting |
| Phase 2 |
| 39 |
| Peking Union Medical CollegeOTHER |
| 1 |
| Apr 2, 2026 |
| clinicaltrials |
| NCT01898494 | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | active not recruiting | Phase 2 | 519 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05318027 | ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy | active not recruiting | Phase 2 | 70 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05387915 | Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 33 | Emory UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06137274 | Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC | recruiting | Phase 2 | 35 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07464366 | The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study(TSEMPRMSGC) | recruiting | Phase 2 | 90 | Ji DongmeiOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05980000 | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma(Rambro2) | active not recruiting | Phase 2 | 37 | Washington University School of MedicineOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07247201 | Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients(AlloNK1) | not yet recruiting | Phase 1 / Phase 2 | 31 | Singapore General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03386357 | Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | terminated | Phase 2 | 115 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07465276 | Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03410615 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | active not recruiting | Phase 2 | 129 | Canadian Cancer Trials GroupNETWORK | 4 | Mar 24, 2026 | clinicaltrials |
| NCT06323460 | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | recruiting | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07491783 | Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial | not yet recruiting | Phase 2 | 52 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03217188 | Proton Re-Irradiation for Recurrent Head and Neck Cancer | completed | Phase 2 | 87 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07320963 | Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. | not yet recruiting | Phase 1 / Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 0 | Mar 20, 2026 | clinicaltrials |
| NCT07485296 | Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)(POST-BIO) | recruiting | Phase 2 | 45 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06876038 | Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions | not yet recruiting | Phase 2 | 65 | University of Massachusetts, BostonOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04251949 | Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis.(MuciLight) | completed | Phase 2 | 28 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04883281 | A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer(DARTBOARD) | completed | Phase 2 | 50 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT01612351 | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | completed | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07092514 | Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC) | recruiting | Phase 2 | 34 | Washington University School of MedicineOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07362979 | Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 243 | Sun Yat-sen UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06332092 | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | active not recruiting | Phase 2 | 46 | Fulgent Pharma LLC.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03360890 | Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors(iPRIME) | active not recruiting | Phase 2 | 46 | University of ChicagoOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06030440 | De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck(DIREKHT2) | recruiting | Phase 2 / Phase 3 | 508 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03313804 | Priming Immunotherapy in Advanced Disease With Radiation | completed | Phase 2 | 76 | John L. Villano, MD, PhDOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT03753919 | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial(DUTHY) | terminated | Phase 2 | 79 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT00939627 | Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04030455 | Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer | active not recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02047474 | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer | completed | Phase 2 | 46 | Yale UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | terminated | Phase 1 / Phase 2 | 42 | GenmabINDUSTRY | 2 | Mar 4, 2026 | clinicaltrials |
| NCT07065630 | Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer | recruiting | Phase 2 | 38 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06208826 | A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy | recruiting | Phase 2 | 268 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447570 | Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC | recruiting | Phase 2 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT02031250 | Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer | completed | Phase 2 | 106 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07044635 | Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.(RAD RAPTORS) | recruiting | Phase 2 | 42 | University of UtahOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07193186 | Anlotinib and Benmelstobart in DTC | not yet recruiting | Phase 2 | 23 | Fudan UniversityOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT05261750 | Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer | active not recruiting | Phase 1 / Phase 2 | 15 | PT. Prodia Stem Cell IndonesiaINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03174275 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07428148 | Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | NYU Langone HealthOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03953976 | INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy | completed | Phase 2 | 67 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | active not recruiting | Phase 1 / Phase 2 | 194 | Merus B.V.INDUSTRY | 9 | Feb 19, 2026 | clinicaltrials |
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06059261 | Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. | recruiting | Phase 2 | 30 | Chongqing University Cancer HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2026source: clinicaltrials